Cocrystal Pharma, Inc.
COCPNasdaq
$0.95
↓ -0.0%Jul 17 close · end-of-day
Price
1Y↓ -43.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$13.1M
Enterprise Value
$13.1M
P/E
—
P/S
—
P/B
3.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$8.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-214.5%
ROIC
-173.4%
Debt / Equity
—
Net Cash
—
Return 1Y
-43.8%
Company profile
Cocrystal Pharma, Inc. focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection.
- CEO
- Sam Lee
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Washington
- Website
- cocrystalpharma.com
Earnings
COCP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$225,000.00—
Diluted EPS-$0.17↓ -26.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.6M | -$14.2M | -$38.8M | -$18.6M | -$17.9M | -$9.0M |
| Net income | -$9.6M | -$14.2M | -$38.8M | -$18.0M | -$17.5M | -$8.8M |
| Diluted EPS | — | — | -$4.77 | -$1.87 | -$1.72 | -$0.78 |
| Operating cash flow | -$9.8M | -$12.7M | -$21.4M | -$14.7M | -$16.5M | -$8.2M |
| Free cash flow | -$10.1M | -$12.8M | -$21.5M | -$14.8M | -$16.5M | -$8.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -476.0% | — | — | — | — | — |
| Net margin | -479.0% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $225,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.4M | -$5.0M | -$3.2M | -$2.3M | -$2.1M | -$2.1M | -$2.5M | -$2.4M |
| Net income | -$5.3M | -$4.9M | -$3.3M | -$2.3M | -$2.1M | -$2.0M | -$2.4M | -$2.3M |
| Diluted EPS | -$0.53 | -$0.49 | -$0.31 | -$0.23 | -$0.20 | -$0.19 | -$0.16 | -$0.17 |
| Operating cash flow | -$3.7M | -$5.1M | -$3.2M | -$2.9M | -$2.2M | -$1.4M | -$1.7M | -$2.3M |
| Free cash flow | -$3.7M | -$5.1M | -$3.2M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -1047.1% |
| Net margin | — | — | — | — | — | — | — | -1021.8% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-24 | FROST PHILLIP MD ET AL | Buy | 20,000 | $1.00 | $19,952.00 | filing |
| 2026-02-06 | FROST PHILLIP MD ET AL | Buy | 50,000 | $0.95 | $47,280.00 | filing |
| 2025-12-31 | FROST PHILLIP MD ET AL | Buy | 50,000 | $0.95 | $47,275.00 | filing |
| 2025-12-30 | FROST PHILLIP MD ET AL | Buy | 20,000 | $0.97 | $19,310.00 | filing |
| 2025-12-26 | FROST PHILLIP MD ET AL | Buy | 40,000 | $0.97 | $38,944.00 | filing |
| 2025-12-24 | FROST PHILLIP MD ET AL | Buy | 25,000 | $0.97 | $24,257.50 | filing |
| 2025-11-26 | FROST PHILLIP MD ET AL | Buy | 2,500 | $0.99 | $2,475.00 | filing |
| 2025-11-26 | FROST PHILLIP MD ET AL | Buy | 1,500 | $1.00 | $1,500.00 | filing |
| 2025-11-25 | FROST PHILLIP MD ET AL | Buy | 20,000 | $0.94 | $18,812.00 | filing |
| 2025-10-28 | FROST PHILLIP MD ET AL | Award | 359,713 | $1.39 | $500,001.07 | filing |
| 2025-10-28 | Hassan Fred | Award | 359,713 | $1.39 | $500,001.07 | filing |
| 2025-10-28 | Martin James Joseph· Co-CEO and CFO | Award | 3,598 | $1.39 | $5,001.22 | filing |
| 2025-10-28 | PFENNIGER RICHARD C JR | Award | 20,000 | — | — | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.